Gubra A/S is a biotechnology company focused on the development and discovery of peptide-based therapies targeting metabolic, fibrotic, and gastrointestinal diseases. As a key player in the biotech se... Gubra A/S is a biotechnology company focused on the development and discovery of peptide-based therapies targeting metabolic, fibrotic, and gastrointestinal diseases. As a key player in the biotech sector, Gubra A/S works at the forefront of scientific research to address complex health challenges by leveraging advanced peptide chemistry and integrated research methodologies. The company's innovative approach significantly impacts the pharmaceutical industry as it enhances the drug development process through collaboration with global pharmaceutical firms. Gubra's commitment to providing cutting-edge solutions not only advances therapeutic options but also contributes to our understanding of metabolic and fibrotic pathways. Headquartered in Denmark, Gubra A/S plays a pivotal role in expanding the capabilities of biotech research, emphasizing the importance of peptide-based treatments in improving patient outcomes across various diseases.Show lessShow more

Disclosures ESG Data Financial Data

GHG Emissions Climate Targets EU Taxonomy Energy Waste Management

Data not available

No Climate Targets data disclosed by Gubra

We reviewed Gubra's website and available disclosure materials for the 2023 reporting period and did not identify any reported Climate Targets data.

If you would like us to review newly published materials or reassess the most recent disclosures, you can submit a data update request.

Would you like us to review Gubra's data?

Start your 30-day free trial to request a data review for Gubra.

Start Free Trial

Legal Center Contact Us